• Ginsenosides and High-Altitude Hypoxia Injury

  2026-09-21

  This study integrates physiological, histological, biochemical, and molecular measurements to show that ginsenosides mitigate hypoxia-associated injury in rat lung and kidney tissues. Its central contribution is linking reduced oxidative and inflammatory damage with regulation of the PHD2/HIF-1α/EPO axis, while also identifying important limits for mechanistic interpretation and translation.

• Amikacin Sulfate: NTM Mechanism and Evidence

  2026-09-21

  Amikacin Sulfate is an aminoglycoside research antibiotic with 30S ribosomal targeting and reported activity against Mycobacterium avium and Staphylococcus aureus. Available product data support investigation of intracellular uptake, granuloma-directed delivery, and therapeutic-index strategies in non-tuberculous mycobacterial models.

• Neomycin sulfate for RNA/DNA Structure Studies

  2026-09-20

  Neomycin sulfate is a water-soluble aminoglycoside antibiotic that turns nucleic-acid folding, ribozyme catalysis, viral RNA recognition, and ion-channel gating into experimentally addressable mechanisms. This guide connects those molecular workflows with microbiome and immune-model design while emphasizing controls, concentration screening, and interpretation limits.

• NVP-BGJ398 Phosphate: FGFR1–3 Research Guide

  2026-09-19

  NVP-BGJ398 phosphate, also called BGJ-398 phosphate, is a selective pan-FGFR1–3 inhibitor for cancer and skeletal-disease research. Its strongest evidence supports FGFR-altered cancer models and pharmacological suppression of FGFR3 signaling in SLC26A2-related chondrodysplasia, while product specifications and assay conditions should be verified before experimental use.

• Wortmannin Workflow for PI3K and IRF7 Studies

  2026-09-18

  Use Wortmannin as a time-controlled PI3K probe to connect PI3K/Akt/mTOR signaling with antiviral, autophagy, and cancer assays. This workflow translates new IRF7–VP3 findings in IBDV research into a hypothesis-testing design while highlighting exposure, solubility, and MLCK-related pitfalls.

• Gentamycin Sulfate for Resistance Research

  2026-09-18

  Gentamycin Sulfate provides a practical 30S-ribosome perturbation tool for bacterial protein synthesis research, susceptibility profiling, and resistance evolution studies. Used beside phenotype-to-genotype workflows, it helps distinguish target-level effects from isolate-specific resistance patterns in Gram-negative models.

• Prochlorperazine: From Antiemetic to Assay Control

  2026-09-17

  Prochlorperazine is a dopamine D2 receptor antagonist with important implications for antiemetic therapy, melanoma research, and translational assay design. This article uses a documented dystonic stroke mimic to explain how pharmacology, safety signals, and experimental controls should shape research workflows.

• CDK9 inhibitor A3294: Protocol and QC Guide

  2026-09-17

  CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for controlled studies of CDK9-dependent transcription elongation and HIV-1 propagation. It is suited to biochemical and cellular assays, but not to pan-CDK experiments, broad claims of cytotoxicity, or long-term storage of prepared solutions.

• Amikacin Sulfate: From MIC to Model Design

  2026-09-16

  Amikacin Sulfate is a powerful benchmark for designing intracellular and non-tuberculous mycobacterial infection assays. This guide connects mechanism, concentration interpretation, delivery biology, and KR-12 peptide research to improve experimental decisions.

• Amikacin Sulfate for Granuloma-Targeted Research

  2026-09-16

  Amikacin Sulfate supports a practical progression from MIC and CFU testing to intracellular uptake and granuloma-localized delivery. This guide translates dendritic-cell targeting research into assay design, workflow controls, and troubleshooting decisions for non-tuberculous mycobacterial studies.

• Neomycin Sulfate as a Translational Mechanism Probe

  2026-09-15

  Neomycin sulfate is more than an aminoglycoside antibiotic: it is a versatile mechanistic probe for RNA/DNA structure interaction studies, ribozyme catalysis, viral RNA recognition, DNA triplex stabilization, and ion-channel function. This thought-leadership perspective shows how to deploy its distinct activities without overextending evidence from microbiome and inflammatory disease models.

• Everolimus (RAD001): mTOR Research Guide

  2026-09-15

  Everolimus, also called RAD001, is an orally bioavailable mTOR pathway inhibitor that forms an FKBP12 complex and suppresses mTOR signaling. Its benchmark antiproliferative values require careful interpretation because in vitro growth inhibition does not equal cell killing.

• ARCA Cy5 EGFP mRNA (5-moUTP): Assay Guide

  2026-09-14

  Learn how ARCA Cy5 EGFP mRNA (5-moUTP), SKU R1009, can separate delivery, localization, and translation variables in mammalian-cell viability and cytotoxicity workflows. This scenario-based guide covers assay design, handling, interpretation, and practical vendor selection.

• DiscoveryProbe FDA-Approved Drug Library for HDT

  2026-09-14

  Learn how the DiscoveryProbe FDA-approved Drug Library can support host-directed infection research through phenotype-first screening, orthogonal validation, and mechanism-aware assay design. A loperamide study provides a practical framework for drug repositioning screening with clinically annotated compounds.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia Models

  2026-09-13

  This study combines genetic ablation, inducible mouse models, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia. NVP-BGJ398 partially improved chondrocyte behavior and skeletal architecture, supporting FGFR3 pathway inhibition as a research direction while leaving important questions about dose, disease severity, and human translation.

8595 records 1/573 page Next 12345 下5页 Last page